• HOME
  • PROCESS
  • OUR SERVICES
    • MARKET ACCESS STRATEGY OPTIMIZATION
    • INTRINSIC VALUE SUBSTANTIATION
    • LOCAL IMPLEMENTATION
  • OUR EXPERTISE
  • REPORTS
  • TEAM
    • OUR TEAM
    • OPPORTUNITIES
  • CONTACT US
  • HOME
  • PROCESS
  • OUR SERVICES
    • MARKET ACCESS STRATEGY OPTIMIZATION
    • INTRINSIC VALUE SUBSTANTIATION
    • LOCAL IMPLEMENTATION
  • OUR EXPERTISE
  • REPORTS
  • TEAM
    • OUR TEAM
    • OPPORTUNITIES
  • CONTACT US

ISMS

ISMS

  • HOME
  • PROCESS
  • OUR SERVICES
    • MARKET ACCESS STRATEGY OPTIMIZATION
    • INTRINSIC VALUE SUBSTANTIATION
    • LOCAL IMPLEMENTATION
  • OUR EXPERTISE
  • REPORTS
  • TEAM
    • OUR TEAM
    • OPPORTUNITIES
  • CONTACT US

REPORTS

Publications

“An integrated modelling methodology for estimating the prevalence of centronuclear myopathy”

“An integrated modelling methodology for estimating global incidence and prevalence of hereditary spastic paraplegia subtypes SPG4, SPG7, SPG11,  and SPG 15”

Posters

“Drug Development: Meeting Future Societal Requirements Converting Outcome Data into Inputs for Cost-Effectiveness Models”

“Aligning Drug Development with Future Patient-Centric Market Access (PACEMA) requirements”

“Long-term durability in cost-effectiveness models of gene therapies: Review of Health Technology Assessment cases”

© 2023 ISMS All Rights Reserved.